Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: Gilead is an independent biopharmaceutical company focused on antivirals, antibacterials, and antifungals. Key marketed products include Viread (HIV), AmBisome (antifungal), DaunoXome (Kaposi's sarcoma), and Vistide (CMV retinitis). The company also holds a collaboration with Roche for Tamiflu (influenza).
Corporate Action: A two-for-one stock split was completed on March 8, 2002; all share and per-share amounts are restated to reflect this.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Total Revenues | $78,416 | $57,836 |
| Net Loss | $(3,850) | $(21,723) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.11) |
| Operating Cash Flow | $(23,115) | $(30,248) |
| Cash & Cash Equivalents (End of Period) | $115,086 | $77,403 |
| Total Liquidity (Cash + Marketable Securities) | $564,669 | N/A |
| Long-Term Debt (Convertible Notes) | $250,000 | $250,000 |
| Accumulated Deficit | $(457,587) | N/A |
Note: Gross margin on product sales improved to 83% in Q1 2002 (Cost of Goods Sold was 17% of net product sales) compared to 77% in Q1 2001.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 36% to $78.4 million, driven primarily by the commercial launch of Viread, which generated $27.2 million in sales (38% of net product sales) in its first full quarter.
- Product Mix Shift: AmBisome sales decreased 5% to $39.8 million, accounting for 56% of product sales in Q1 2002 compared to 93% in Q1 2001. The decline was partially attributed to foreign currency fluctuations.
- Expense Dynamics:
- R&D Expenses: Decreased 34% to $33.6 million, largely due to the absence of a $10.6 million upfront payment to Cubist Pharmaceuticals recognized in Q1 2001 and reduced Phase III clinical costs for Viread.
- SG&A Expenses: Increased 81% to $39.8 million due to global marketing efforts and sales force expansion for the Viread launch.
- Profitability: Net loss narrowed significantly to $3.9 million from $21.7 million in the prior year, aided by a $1.0 million income tax benefit and reduced R&D spend.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2002 R&D Forecast: Expected to be $140 million to $150 million, representing a 15% to 25% decrease from 2001 levels.
- 2002 SG&A Forecast: Expected to be $180 million to $190 million, a 45% to 55% increase from 2001, driven by Viread marketing and preparation for adefovir dipivoxil (Hepatitis B) launch.
- Cost of Goods Sold: Expected to be approximately 20% of net product sales for the full year 2002, an improvement from 23% in 2001.
- Liquidity: Management believes existing capital resources ($564.7 million in cash and marketable securities) are adequate for the foreseeable future.
Risks and Contingencies
- Market Acceptance: Significant reliance on Viread and AmBisome; competitive pressure from lower-priced or newly approved products could reduce revenues.
- Foreign Currency: A majority of sales are denominated in foreign currencies; a stronger U.S. dollar negatively impacts reported revenues. The company began hedging forecasted sales in January 2002.
- Accounts Receivable: Significant past-due receivables ($33.8 million) exist in Greece, Spain, Portugal, and Italy, with $20.6 million over 120 days past due, though management believes they are collectible.
- Regulatory: Risks associated with FDA and foreign agency approvals for pipeline products like adefovir dipivoxil.
Unusual Items
- Subsequent Event: In April 2002, Gilead signed a licensing agreement with GlaxoSmithKline (GSK) for adefovir dipivoxil in Asia, Latin America, and other territories. GSK paid a $10 million upfront fee, with up to $30 million in milestone payments and royalties.
- Asset Sale: Completed the sale of oncology assets to OSI Pharmaceuticals in December 2001, impacting future R&D scope.
Investor Verification Checklist
- Viread Sales Trajectory: Verify if Viread sales growth continues to offset the decline in AmBisome sales as projected.
- European Receivables: Monitor the collection status of the $33.8 million in past-due receivables from Greece, Spain, Portugal, and Italy.
- SG&A Run Rate: Confirm that SG&A expenses align with the $180M-$190M full-year guidance amidst the Viread launch.
- Foreign Exchange Impact: Assess the effectiveness of the new hedging strategy implemented in January 2002 against currency fluctuations.
- Regulatory Milestones: Track the approval status of adefovir dipivoxil for Hepatitis B, which is critical for future revenue diversification.